Prospective Cohort Study of the Risk of Recurrent Atrial Fibrillation After Radiofrequency Ablation
Launched by PEKING UNIVERSITY THIRD HOSPITAL · Nov 28, 2022
Trial Information
Current as of January 22, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying patients with atrial fibrillation, which is a type of irregular heartbeat. The researchers want to understand what factors might cause atrial fibrillation to come back after a treatment called catheter ablation, a procedure that helps restore a normal heart rhythm. By collecting information from patients who have undergone this treatment at Peking University Third Hospital, they aim to identify risks and improve how doctors manage patients with this condition.
To participate in this study, you need to be over 18 years old and have been diagnosed with atrial fibrillation through an electrocardiogram (a test that checks your heart's rhythm). Unfortunately, if you have certain health issues like severe blood disorders, cancer, or conditions that significantly affect your mobility or mental state, you may not be eligible. If you join the study, you can expect regular check-ups and follow-ups to monitor your heart health and gather important information about your recovery. Your participation could help improve treatment and care for others with atrial fibrillation in the future.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1) Age \> 18
- • 2) ECG or holter electrocardiogram confirmed atrial fibrillation
- Exclusion Criteria:
- • 1) Hematological diseases, autoimmune diseases and malignant tumors
- • 2) Immobility caused by hemiplegia or severe trauma
- • 3) The expected survival time is less than 2 years
- • 4) Poor compliance and high risk of expected loss of follow-up
- • 5) Disorders of consciousness or Alzheimer's disease
About Peking University Third Hospital
Peking University Third Hospital is a leading medical institution in China, renowned for its commitment to advanced healthcare, innovative research, and comprehensive clinical services. As a prominent sponsor of clinical trials, the hospital emphasizes the integration of cutting-edge scientific research with patient-centered care to enhance therapeutic outcomes. With a multidisciplinary approach, the institution fosters collaboration among top-tier medical professionals and researchers, striving to contribute to the global medical community through rigorous clinical studies that address pressing health challenges. Its dedication to ethical standards and regulatory compliance ensures the safety and efficacy of new treatments, ultimately aiming to improve patient care and outcomes on both a national and international scale.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Beijing, , China
People applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Discussion 0
Similar Trials